Ubs Group Ag Bio Restorative Therapies, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Bio Restorative Therapies, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 16,297 shares of BRTX stock, worth $37,320. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,297

Previous 693 2251.66%

Holding current value

$37,320

Previous $1,000 2100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.33 - $1.73 $20,753 - $26,994	15,604 Added 2251.66%	16,297 $22,000
Q3 2024 Nov 14, 2024	SELL	$1.32 - $1.98 $35,798 - $53,697	-27,120 Reduced 97.51%	693 $1,000
Q2 2024 Aug 13, 2024	BUY	$1.15 - $2.22 $31,018 - $59,880	26,973 Added 3211.07%	27,813 $56,000
Q1 2024 May 13, 2024	BUY	$1.28 - $3.45 $954 - $2,573	746 Added 793.62%	840 $1,000
Q4 2023 Feb 09, 2024	BUY	$1.74 - $2.28 $161 - $212	93 Added 9300.0%	94 $0
Q3 2023 Nov 09, 2023	SELL	$1.45 - $4.57 $4,463 - $14,066	-3,078 Reduced 99.97%	1 $0
Q2 2023 Aug 11, 2023	BUY	$3.49 - $6.49 $5,179 - $9,631	1,484 Added 93.04%	3,079 $13,000
Q1 2023 May 12, 2023	BUY	$2.67 - $3.61 $4,255 - $5,754	1,594 Added 159400.0%	1,595 $5,000
Q4 2022 Feb 08, 2023	SELL	$2.58 - $3.68 $4,040 - $5,762	-1,566 Reduced 99.94%	1 $0
Q3 2022 Nov 10, 2022	BUY	$2.46 - $3.47 $2,627 - $3,705	1,068 Added 214.03%	1,567 $5,000
Q2 2022 Aug 10, 2022	BUY	$2.95 - $5.85 $1,469 - $2,913	498 Added 49800.0%	499 $1,000
Q1 2022 May 16, 2022	SELL	$3.3 - $5.69 $999 - $1,724	-303 Reduced 99.67%	1 $0
Q4 2021 Feb 14, 2022	BUY	$4.02 - $18.0 $1,222 - $5,472	304 New	304 $1,000

Others Institutions Holding BRTX

# of Institutions

Shares Held

250K

Call Options Held

Put Options Held

View Full List

About BioRestorative Therapies, Inc.

Ticker BRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 3,650,030
Market Cap $8.36M
Description
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtx...

More about BRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account